Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An uncommon carcinoma arising from the cervix. It is composed of malignant glandular epithelial cells and malignant squamous epithelial cells.
Biomarker and diagnostic research for cervical adenosquamous carcinoma has been reported in the published literature.
13 clinical trials registered, 2 recruiting. Interventions under study include procedural interventions, drug therapy, other interventions, and biologic therapy. Pipeline includes 2 PHASE3, 4 PHASE2, 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06543576](https://clinicaltrials.gov/study/NCT06543576) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 12:35 PM UTC
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer |
PHASE1 |
Jonsson Comprehensive Cancer Center |
RECRUITING |
[NCT07454642](https://clinicaltrials.gov/study/NCT07454642) | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | PHASE1 | Avacta Life Sciences Ltd | RECRUITING |
36 publications have been identified in PubMed for cervical adenosquamous carcinoma. Research spans Diagnostic / Biomarker (22%), Case Report / Case Series (19%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 8 | 22% |
Patient case studies | 7 | 19% |
Research summaries | 6 | 17% |
Disease patterns and progression | 6 | 17% |
Clinical study results | 5 | 14% |
Laboratory research | 3 | 8% |
Other research | 1 | 3% |
Zhang Z (2026). [PMID: 41580208](https://pubmed.ncbi.nlm.nih.gov/41580208/). *Hum Pathol*. [Basic Science / Preclinical]
Zhu A (2026). [PMID: 41311114](https://pubmed.ncbi.nlm.nih.gov/41311114/). *Int J Gynaecol Obstet*. [Diagnostic / Biomarker]
Andrade LALA (2026). [PMID: 41731708](https://pubmed.ncbi.nlm.nih.gov/41731708/). *Int J Surg Pathol*. [Basic Science / Preclinical]
Poulain F (2026). [PMID: 42207638](https://pubmed.ncbi.nlm.nih.gov/42207638/). *Cell Rep*. [Basic Science / Preclinical]
Umemiya M (2026). [PMID: 42172494](https://pubmed.ncbi.nlm.nih.gov/42172494/). *J Gynecol Oncol*. [Diagnostic / Biomarker]
Arora I (2026). [PMID: 41569320](https://pubmed.ncbi.nlm.nih.gov/41569320/). *Virchows Arch*. [Case Report / Case Series]
Donohoe F (2026). [PMID: 41774953](https://pubmed.ncbi.nlm.nih.gov/41774953/). *Int J Gynecol Cancer*. [Diagnostic / Biomarker]
Liu Y (2026). [PMID: 41700930](https://pubmed.ncbi.nlm.nih.gov/41700930/). *J Med Virol*. [Epidemiology / Natural History]
Lorusso D (2025). [PMID: 39393777](https://pubmed.ncbi.nlm.nih.gov/39393777/). *Ann Oncol*. [Clinical Trial Publication]
Ozcivit Erkan IB (2025). [PMID: 39641624](https://pubmed.ncbi.nlm.nih.gov/39641624/). *Int J Gynaecol Obstet*. [Review / Meta-Analysis]
AI-curated news mentioning cervical adenosquamous carcinoma
Updated May 20, 2026
A new case series highlights the complexities of adenosquamous carcinoma of the esophagus, a rare and aggressive form of cancer. This research contributes to the understanding of its clinical behavior and potential treatment challenges.